synthekine.comHealthcare / BioTech & PharmaFounded: 2018Funding to Date: $288.61MM
Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
01/06/2023 | Series C | $100MM | $xx.xx | $572.91MM | The Column Group | |
Price per Share
$xx.xx
Shares Outstanding
38,737,618
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
The Column Group
|
||||||
06/10/2021 | Series B | $107.5MM | $xx.xx | $418.94MM | Canaan Partners, Deerfield Management, Emerson Collective, Janus Henderson Investors, Lilly Asia Ventures, Omega Funds, Ra Capital Management, Rock Springs Capital, Samsara Biocapital, Tcg X, The Column Group | |
Price per Share
$xx.xx
Shares Outstanding
37,478,647
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Deerfield Management, Emerson Collective, Janus Henderson Investors, Lilly Asia Ventures, Omega Funds, Ra Capital Management, Rock Springs Capital, Samsara Biocapital, Tcg X, The Column Group
|
||||||
09/17/2020 | Series A-1 | $40MM | $xx.xx | $130.56MM | Canaan Partners, Samsara Biocapital, The Column Group | |
Price per Share
$xx.xx
Shares Outstanding
31,999,998
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2
Key Investors
Canaan Partners, Samsara Biocapital, The Column Group
|
||||||
09/17/2020 | Series A | $41.11MM | $xx.xx | $130.56MM | Canaan Partners, Samsara Biocapital, The Column Group | |
Price per Share
$xx.xx
Shares Outstanding
41,111,110
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
3
Key Investors
Canaan Partners, Samsara Biocapital, The Column Group
|